Literature DB >> 16781758

Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding.

Thomas Fothergill1, Nigel A J McMillan.   

Abstract

We have previously shown that human papillomavirus virus-like particles (VLPs) are able to activate the Ras/MAP kinase pathway. Ras can also elicit an anti-apoptotic signal via PI3-kinase so we investigated this further. Here we show that binding of VLPs from HPV types 6b, 18, 31, 35 and BPV1 results in activation of PI3-kinase. Activation was achieved by either L1 or L1/L2 VLPs and was dependent on both VLP-cell interaction and correct conformation of the virus particle. VLP-induced PI3-kinase activity resulted in efficient downstream signaling to Akt and consequent phosphorylation of FKHR and GSK3beta. We also present evidence that PV signaling is activated via the alpha6beta4 integrin. These data suggest that papillomaviruses use a common receptor that is able to signal through to Ras. Combined activation of the Ras/MAP kinase and PI3-kinase pathways may be beneficial for the virus by increasing cell numbers and producing an environment more conducive to infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781758     DOI: 10.1016/j.virol.2006.05.002

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  33 in total

1.  Usage of heparan sulfate, integrins, and FAK in HPV16 infection.

Authors:  Cynthia Y Abban; Patricio I Meneses
Journal:  Virology       Date:  2010-05-02       Impact factor: 3.616

2.  Rotavirus replication in intestinal cells differentially regulates integrin expression by a phosphatidylinositol 3-kinase-dependent pathway, resulting in increased cell adhesion and virus yield.

Authors:  Peter Halasz; Gavan Holloway; Stephen J Turner; Barbara S Coulson
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 3.  The evolving field of human papillomavirus receptor research: a review of binding and entry.

Authors:  Adam B Raff; Andrew W Woodham; Laura M Raff; Joseph G Skeate; Lisa Yan; Diane M Da Silva; Mario Schelhaas; W Martin Kast
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 4.  Cruising the cellular highways: How human papillomavirus travels from the surface to the nucleus.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G Guion; Martin Sapp
Journal:  Virus Res       Date:  2016-10-29       Impact factor: 3.303

5.  Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Authors:  Diane M Da Silva; Carly A Movius; Adam B Raff; Heike E Brand; Joseph G Skeate; Michael K Wong; W Martin Kast
Journal:  Virology       Date:  2014-02-17       Impact factor: 3.616

6.  Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway during porcine circovirus type 2 infection facilitates cell survival and viral replication.

Authors:  Li Wei; Shanshan Zhu; Jing Wang; Jue Liu
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

Review 7.  Concepts of papillomavirus entry into host cells.

Authors:  Patricia M Day; Mario Schelhaas
Journal:  Curr Opin Virol       Date:  2013-12-14       Impact factor: 7.090

8.  Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy.

Authors:  Zurab Surviladze; Rosa T Sterk; Sergio A DeHaro; Michelle A Ozbun
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

9.  Human papillomavirus type 8 E2 protein unravels JunB/Fra-1 as an activator of the beta4-integrin gene in human keratinocytes.

Authors:  Monika Oldak; Radoslaw B Maksym; Tanya Sperling; Moshe Yaniv; Hans Smola; Herbert J Pfister; Jacek Malejczyk; Sigrun Smola
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

10.  Chimeric recombinant rotavirus-like particles as a vehicle for the display of heterologous epitopes.

Authors:  Andrea Peralta; Paula Molinari; Oscar Taboga
Journal:  Virol J       Date:  2009-11-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.